Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 985-986

  Breccia, Massimo ^a   Loglisci, Giuseppina ^a   Cannella, Laura ^a   Finsinger, Paola ^a   Mancini, Marco ^a   Serrao, Alessandra ^a   Santopietro, Michelina ^a   Salaroli, Adriano ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; DRUG RESPONSE; FEMALE; FRENCH PROGNOSTIC SCORE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LETTER; MAJOR CLINICAL STUDY; MALE; MONOCYTIC LEUKEMIA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SCORING SYSTEM; SOLID TUMOR; SURVIVAL TIME;

AZACITIDINE; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

EID: 84859929247     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.643408     Document Type: Letter

References (5)

1. Silverman LR, Demakos EP, Peterson BL, et al. Randomized, controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002;20:2429-2440. (Pubitemid 34525728)
2. F enaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Effi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open label, phase III study. Lancet Oncol 2009;10:223-232.
3. Itzykson R, Th epot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403-411.
4. Vardiman JW, Th iele J, Arber DA, et al. Th e 2008 revision of the World Health Organization (WHO) classifi cation of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114: 937-951.
5. C heson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modifi cation of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-425. (Pubitemid 44061337)